Combination Therapy with Thalidomide, Incadronate, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

  • Naoya Ochiai
  • Noriko Yamada
  • Ryo Uchida
  • Shin-ichi Fuchida
  • Akira Okano
  • Mayumi Hatsuse
  • Masashi Okamoto
  • Eishi Ashihara
  • Chihiro Shimazaki
Article

Abstract

The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma. The protocol, consisting of 300 mg/day of thalidomide administered orally, intravenous incadronate (10 mg/day) administered weekly, and 12 mg/day dexamethasone for 4 days, was repeated every 3 weeks. Evaluations of efficacy and toxicity were carried out every 3 weeks and were continued for 3 cycles. Three patients were excluded during the study because of apnea, severe somnolence, and pancytopenia. Of 9 evaluated patients, the partial responses achieved in 3 patients and the minor responses achieved in 4 patients corresponded to a response rate of 78% according to the criteria of the European Group for Blood and Marrow Transplantation. In addition, painful osteolytic symptoms improved rapidly after 1 cycle of TID therapy in the 10 patients evaluated. These data suggest that TID is a feasible and promising therapeutic approach for refractory and relapsed multiple myeloma.

Key words

Multiple myeloma Thalidomide Incadronate Dexamethasone 

References

  1. 1.
    Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91–97.CrossRefPubMedGoogle Scholar
  2. 2.
    Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789–793.PubMedGoogle Scholar
  3. 3.
    Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883.CrossRefPubMedGoogle Scholar
  4. 4.
    Bjokstrand B, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88:4711–4718.Google Scholar
  5. 5.
    Lokhorst A, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031–3037.CrossRefPubMedGoogle Scholar
  6. 6.
    Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001;97:2574–2579.CrossRefPubMedGoogle Scholar
  7. 7.
    Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002;100:755–760.CrossRefPubMedGoogle Scholar
  8. 8.
    Shimazaki C, Fujii H, Yoshida T, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group (JMSG). Int J Hematol. 2005;81:342–348.CrossRefPubMedGoogle Scholar
  9. 9.
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalido-mide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571.CrossRefPubMedGoogle Scholar
  10. 10.
    Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000;109:89–96.CrossRefPubMedGoogle Scholar
  11. 11.
    Hus M, Dmoszynska A, Soroka-Woitaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma. Haematolog-ica. 2001;86:404–408.Google Scholar
  12. 12.
    Raje N, Anderson K. Thalidomide—a revival story. N Engl J Med. 1999;18:1606–1609.CrossRefGoogle Scholar
  13. 13.
    Yaccoby S, Johnson CL, Maahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood. 2002;100:4162–4168.CrossRefPubMedGoogle Scholar
  14. 14.
    Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943–2950.PubMedGoogle Scholar
  15. 15.
    Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol. 2001;12:991–995.CrossRefPubMedGoogle Scholar
  16. 16.
    Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica. 2001;86:399–403.PubMedGoogle Scholar
  17. 17.
    Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol. 2003;121:768–771.CrossRefPubMedGoogle Scholar
  18. 18.
    Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004;73:98–103.CrossRefPubMedGoogle Scholar
  19. 19.
    Palumbo A, Bertola A, Falco P, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J. 2004;5:318–324.CrossRefPubMedGoogle Scholar
  20. 20.
    Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood. 2001;98:3846–3848.CrossRefPubMedGoogle Scholar
  21. 21.
    Singhal S, Mehta J. Novel therapies in multiple myeloma. Int J Hematol. 2003;77:226–231.CrossRefPubMedGoogle Scholar
  22. 22.
    Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:488–493.CrossRefPubMedGoogle Scholar
  23. 23.
    Ashcroft AJ, Davies FE, Morgan GJ. An etiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol. 2003;4:284–292.CrossRefPubMedGoogle Scholar
  24. 24.
    Shipman CM, Rogers MJ, Vanderkerken K, et al. Bisphosphonates— mechanisms of action in multiple myeloma. Acta Oncol. 2000;39:829–835.CrossRefPubMedGoogle Scholar
  25. 25.
    Shipman CM, Rogers MJ, Apperley JF Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol. 1997;98:665–672.CrossRefPubMedGoogle Scholar
  26. 26.
    Takahashi R, Shimazaki C, Inaba T, et al. A newly developed bis-phosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res. 2001;25:77–83.CrossRefPubMedGoogle Scholar
  27. 27.
    Corradini P, Ladetto M, Voena C, et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood. 1993;81:2708–2713.PubMedGoogle Scholar
  28. 28.
    Durie BGM. Staging and kinetics of multiple myeloma. Semin Oncol. 1986;13:300–309.PubMedGoogle Scholar
  29. 29.
    Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1975;36:842–854.CrossRefPubMedGoogle Scholar
  30. 30.
    Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol. 1998;102:1115–1123.CrossRefPubMedGoogle Scholar
  31. 31.
    Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492–494.CrossRefPubMedGoogle Scholar
  32. 32.
    Ciepluch H, Braden W, Hellmann A. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. Med Sci Monit. 2002;8:PI31-PI36.PubMedGoogle Scholar
  33. 33.
    Ochiai N, Shimazaki C, Uchida R, et al. Thalidomide therapy in patients with refractory or relapsed multiple myeloma [in Japanese]. Rinsho Ketsueki. 2002;43:1045–1049.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2005

Authors and Affiliations

  • Naoya Ochiai
    • 1
  • Noriko Yamada
    • 1
  • Ryo Uchida
    • 1
  • Shin-ichi Fuchida
    • 1
  • Akira Okano
    • 1
  • Mayumi Hatsuse
    • 2
  • Masashi Okamoto
    • 1
  • Eishi Ashihara
    • 1
  • Chihiro Shimazaki
    • 1
  1. 1.Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of MedicineKyotoJapan
  2. 2.Shakaihoken Kyoto HospitalKyotoJapan

Personalised recommendations